证券代码：688083 证券简称：中望软件 公告编号：2025-053 广州中望龙腾软件股份有限公司 关于向 2024 年限制性股票激励计划激励对象 预留授予限制性股票的公告 本公司董事会及全体董事保证本公告内容不存在虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 广州中望龙腾软件股份有限公司（以下简称"公司"）《2024 年限制性股 票激励计划（草案）》（以下简称"《激励计划》"）规定的 2024 年限制性股 票激励计划（以下简称"本次激励计划"）预留授予条件已经成就，根据公司 会第十七次会议，审议通过了《关于向 2024 年限制性股票激励计划激励对象授 予预留限制性股票的议案》，同意以 2025 年 8 月 29 日为授予日，以 36.18 元/ 股的授予价格向 3 名激励对象授予 2.6976 万股限制性股票。现将有关事项说明 如下： 一、限制性股票授予情况 （一）本次限制性股票授予已履行的决策程序和信息披露情况 了《关于 <广州中望龙腾软件股份有限公司 ensp="ensp" 年限制性股票激励计划="年限制性股票激励计 划" 草案="草案"> ...

Core Viewpoint - The company, Shaanxi Yuanjie Semiconductor Technology Co., Ltd., has announced a new stock incentive plan aimed at enhancing corporate governance, attracting and retaining key personnel, and aligning the interests of shareholders, the company, and core teams for long-term development [2][19]. Group 1: Stock Incentive Plan Overview - The stock incentive plan involves granting a total of 634,500 restricted stocks, accounting for approximately 0.74% of the company's total share capital as of the announcement date [1][3]. - The plan includes an initial grant of 507,600 shares (80% of the total) and a reserved portion of 126,900 shares (20% of the total) [1][3]. Group 2: Purpose of the Incentive Plan - The primary objective is to improve the company's governance structure and establish a long-term incentive mechanism to motivate management and core personnel, thereby enhancing team cohesion and competitiveness [2][19]. - The plan aims to ensure the alignment of interests among shareholders, the company, and the core team, focusing on the long-term development of the company [2][19]. Group 3: Stock Grant and Source - The incentive plan will utilize restricted stocks as the incentive tool, sourced from shares repurchased in the secondary market or newly issued shares directed to the incentive recipients [3][11]. - The initial grant price for the restricted stocks is set at 149.09 yuan per share, with adjustments possible based on corporate actions prior to the completion of the stock grant [11][12]. Group 4: Eligibility and Distribution of Incentives - Eligible recipients include directors, senior management, core technical personnel, and key business staff, with specific criteria outlined in relevant laws and regulations [4][5]. - The distribution of the restricted stocks among recipients is structured to ensure that no individual receives more than 1% of the total share capital through all active incentive plans [8][9]. Group 5: Performance Assessment and Conditions - The performance assessment for the incentive plan is based on annual revenue targets, with specific goals set for each assessment period from 2025 to 2028 [16][19]. - The plan stipulates that if the company fails to meet the performance targets, the corresponding restricted stocks will not vest and will be forfeited [16][19]. Group 6: Implementation and Adjustment Procedures - The plan's implementation requires approval from the board of directors and must follow a structured process for granting, vesting, and potential adjustments to the number of shares or grant price due to corporate actions [20][23]. - Adjustments to the number of restricted stocks or their grant price will be made in accordance with specific formulas if corporate actions such as stock splits or dividends occur [24][25].

广州中望龙腾软件股份有限公司董事会 超过股权激励计划提交股东会时公司股本总额的 20%。 上市公司实际控制人及其配偶、父母、子女。 广州中望龙腾软件股份有限公司 （截至授予日） 一、限制性股票激励计划预留授予的分配情况表 获授的限制 占授予限制性 占本激励计划公 姓名 国籍 职务 性股票数量 股票总数的比 告日股本总额的 （股） 例 比例 （一）董事、高级管理人员及核心技术人员 吕成伟 中国 董事 8,992 0.6005% 0.0053% （二）其他激励对象 骨干员工（共计 2 人） 17,984 1.2011% 0.0106% 合计 26,976 1.8016% 0.0159% 注：1、上述任何一名激励对象通过全部在有效期内的股权激励计划获授的本公司股票 均未超过公司总股本的 1%。公司全部在有效期内的激励计划所涉及的标的股票总数累计不 ...

Core Viewpoint - The company plans to repurchase shares through a centralized bidding process, with a total repurchase amount ranging from 500 million to 960 million yuan, aimed at employee stock ownership plans or equity incentives [2][3][4] Summary by Sections Repurchase Plan Overview - The repurchase plan was approved by more than two-thirds of the board members and does not require shareholder meeting approval [2] - The repurchase will be conducted within 12 months after board approval [2] - The maximum repurchase price is set at 8 yuan per share [3][4] Financial Details - The estimated repurchase amount is between 500 million yuan and 960 million yuan [3] - The funding sources for the repurchase will be the company's own funds and other self-raised funds [3][5] - The total number of shares to be repurchased is estimated to be between 62.5 million and 120 million shares, representing 1.35% to 2.60% of the total share capital [4] Purpose and Use of Repurchased Shares - All repurchased shares will be used for equity incentives or employee stock ownership plans [4][10] - The company aims to enhance investor confidence and promote long-term sustainable development through this repurchase [10] Impact on Company Structure - The repurchase is not expected to significantly impact the company's daily operations, financial status, or debt repayment capabilities [9][10] - The repurchase will not lead to a change in control of the company, and the share distribution will remain compliant with listing requirements [9][10] Compliance and Disclosure - The company has established a dedicated securities account for the repurchase [13] - The company will disclose information regarding the progress of the repurchase in a timely manner [13]

陕西源杰半导体科技股份有限公司董事会薪酬与考核委员会 关于 2025 年限制性股票激励计划相关事项的核查意见 陕西源杰半导体科技股份有限公司（以下简称"公司"）董事会薪酬与考 核委员会根据《中华人民共和国公司法》（以下简称《公司法》）、《中华人民共 和国证券法》（以下简称《证券法》）、《上市公司股权激励管理办法》（以下简称 《管理办法》）、《上海证券交易所科创板股票上市规则》（以下简称《上市规 则》）、《科创板上市公司自律监管指南第4号——股权激励信息披露》等有关法 律法规和规范性文件及《陕西源杰半导体科技股份有限公司章程》（以下简称 《公司章程》）的规定，对公司2025年限制性股票激励计划（以下简称"本次激 励计划"）相关事项进行了核查，发表核查意见如下： 一、公司不存在《管理办法》等法律法规规定的禁止实施股权激励计划的 情形，包括： （一）最近一个会计年度财务会计报告被注册会计师出具否定意见或者无 法表示意见的审计报告； （二）最近一个会计年度财务报告内部控制被注册会计师出具否定意见或 无法表示意见的审计报告； （三）上市后最近36个月内出现过未按法律法规、《公司章程》、公开承诺 进行利润分配的情形； （ ...

8月29日，北京英诺特生物技术股份有限公司(以下简称"英诺特")发布2025年半年报。报告期内，公司 营收实现2.76亿元，归母净利润实现1.25亿元。2022年至今，受益于国家分级诊疗体系不断推进、多项 呼吸道相关临床实践指南等多方面因素，公司业务不断发展。 随着我国人口老龄化加剧，公司于报告期内战略进入包括阿尔茨海默病等在内的神经系统疾病检测领 域。3月22日英诺特与Quanterix举行战略签约发布会，Quanterix是一家数字化生物标志物分析公司，其 研发的检测技术Simoa能够检测到传统方法无法识别的极低浓度生物标志物，为疾病早期诊断、治疗监 测和药物研发提供了前所未有的可能性。 报告期内，受疾病流行趋势、病患就诊习惯、税收政策等多方面因素较去年同期发生变化的影响，公司 业绩出现阶段性下滑，但较2022年上半年以及2023年上半年科创板上市初期显著提升。虽然面临营收压 力，但英诺特依旧笃定执行年初制定的经营计划，持续加大研发创新力度与加快技术平台成果转化速 度，继续保持较高的研发投入占比。 与此同时，为调动员工积极性，吸引和留住优秀人才，英诺特计划实施股权激励。8月29日，半年报披 露当日，公司同 ...

Investment Rating - The report maintains an "Accumulate" rating for the company [1] Core Views - In the first half of 2025, the company achieved a revenue of 350 million yuan, representing a year-on-year growth of 16%, with a net profit attributable to shareholders of 16 million yuan, also showing a year-on-year increase of 0.16% [2] - In Q2 alone, the company recorded a revenue of 190 million yuan, a year-on-year increase of 20%, and a net profit of 12 million yuan, reflecting a significant year-on-year growth of 829% [2] - The revenue growth is primarily driven by high-end products and solutions, with high-end digital oscilloscopes (bandwidth ≥ 2GHz) sales increasing by 41% year-on-year, accounting for 30% of the oscilloscope segment's revenue [2] - The sales revenue from solutions reached approximately 62 million yuan in the first half of 2025, marking a year-on-year growth of 44% [2] Financial Performance Summary - The company's gross profit margin for the first half of 2025 was 55.4%, a decrease of 1.3 percentage points year-on-year, while the net profit margin was 4.6%, down 0.33 percentage points year-on-year [3] - The decline in gross margin is attributed to increased production costs at the Malaysian facility, changes in product mix, and the impact of U.S. tariffs [3] - The company’s expense ratio decreased by 5.3 percentage points year-on-year to 59.4%, benefiting from economies of scale [3] Employee Incentives and Global Strategy - The company announced a restricted stock incentive plan in April 2025, proposing to grant 2 million shares to 99 core employees, representing 1.0% of the total share capital [4] - The incentive plan aims to bind core employees and reflects the company's confidence in growth, with performance targets set for revenue and net profit growth [4] - Additionally, the company is preparing for a Hong Kong stock listing to accelerate its global branding and product strategy [4]

Core Points - The company announced the achievement of the first unlock condition for the reserved grant portion of the "Qihang No. 2" restricted stock incentive plan, allowing 64 eligible participants to unlock a total of 662,500 shares, which represents approximately 0.08% of the company's total share capital [1][5][10] Group 1: Incentive Plan Details - The "Qihang No. 2" restricted stock incentive plan was approved and implemented following the necessary decision-making procedures and information disclosure [5][10] - The first unlock period for the reserved grant portion is set to begin on September 23, 2025, and will last until the last trading day within 24 months from the completion of the reserved grant registration [5][8] - The total number of restricted stocks granted in this plan is 19,079,000 shares, with the registration completed at the Shanghai branch of China Securities Depository and Clearing Co., Ltd. [3][4] Group 2: Unlock Conditions - The unlock conditions for the restricted stocks include the absence of negative audit opinions, compliance with profit distribution regulations, and no legal restrictions on stock incentives [6][7][8] - The performance assessment for the incentive plan is based on the company's net profit growth rate, which must cumulatively reach at least 65% over the assessment years of 2023 to 2025 [8][9] - The company's net profit for 2023 was approximately 627.21 million yuan, and for 2024, it was approximately 715.59 million yuan, achieving a cumulative growth rate of 69.88% [8][9] Group 3: Approval and Compliance - The board of directors and the remuneration and assessment committee confirmed that the unlock conditions have been met and that the decision-making process complies with relevant laws and regulations [10] - Legal opinions affirm that the necessary approvals and authorizations for the unlock conditions have been obtained, aligning with the Company Law and Securities Law [10]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： ? 限制性股票回购数量：59,500 股 ? 限制性股票回购价格：6.27 元/股 北京四方继保自动化股份有限公司（以下简称"公司"）于2025年8月28日 召开第八届董事会第二次会议，审议通过了《关于回购注销部分激励对象已获授 但尚未解除限售的限制性股票及调整回购价格的议案》。鉴于公司启航2号限制 性股票激励计划中2名激励对象离职，不再具备激励对象资格，公司董事会同意 对其已获授但尚未解除限售的全部限制性股票共计59,500股进行回购注销。同时， 因公司2024年年度权益分派方案已实施完毕，对回购价格进行相应调整。现将有 关事项说明如下： 证券代码：601126 证券简称：四方股份 公告编号：2025-038 北京四方继保自动化股份有限公司 关于回购注销部分激励对象已获授但尚未解除限售 的限制性股票及调整回购价格的公告 人买卖公司股票情况的自查报告》。 八次会议，审议通过了《关于向启航2号限制性股票激励计划激励对象首次授予 限制性股票的议案》，公司独立董事 ...

上海礼丰律师事务所(以下简称"本所")接受杭州奥泰生物技术股份有限公司 (以下简称"奥泰生物"或"公司")的委托，指派本所律师根据《中华人民共和国公 司法》(以下简称"《公司法》")、 《中华人民共和国证券法》(以下简称"《证券法》")、 中国证券监督管理委员会(以下简称"中国证监会")《上市公司股权激励管理办法》 (以下简称"《管理办法》")等法律、法规、规范性文件(以下统称"法律法规")及《杭 州奥泰生物技术股份有限公司章程》(以下简称"《公司章程》")的规定就公司实 施 2024 年限制性股票激励计划(以下简称"本激励计划")的授予价格调整(以下简 称"本次调整")及预留授予(以下简称"本次授予")所涉及的相关事项出具本法律 意见书。 为出具本法律意见书，本所依据《律师事务所从事证券法律业务管理办法》 和《律师事务所证券法律业务执业规则(试行)》等有关规定，收集了相关证据材 料，查阅了按规定需要查阅的文件以及本所认为必须查阅的其他文件，包括但不 限于公司提供的有关政府部门的批准文件、有关记录、资料、证明。在公司保证 提供了本所为出具本法律意见书所要求公司提供的原始书面材料、副本材料、复 印材料、说明与承 ...